What were Amrutanjan Health Care Ltd's latest quarterly results?
Amrutanjan Health Care Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: 0.0%
- Revenue Growth YoY: +14.6%
- Operating Margin: 18.0%
Amrutanjan Health Care Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 25.5. ROE: 16.5%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
Amrutanjan Health Care Ltd's latest quarterly results (Dec 2025) show
Amrutanjan Health Care Ltd's current PE ratio is 25.5x.
Amrutanjan Health Care Ltd's price-to-book ratio is 4.3x.
Amrutanjan Health Care Ltd's fundamental strength based on key financial ratios
Amrutanjan Health Care Ltd has a debt-to-equity ratio of N/A.
Amrutanjan Health Care Ltd's return ratios over recent years
Amrutanjan Health Care Ltd's operating cash flow is positive (FY2025).
Amrutanjan Health Care Ltd's current dividend yield is 0.90%.
Amrutanjan Health Care Ltd's shareholding pattern (Dec 2025)
Amrutanjan Health Care Ltd's promoter holding has remained stable recently.
Amrutanjan Health Care Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Amrutanjan Health Care Ltd may be worth studying
Amrutanjan Health Care Ltd investment thesis summary:
Amrutanjan Health Care Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.